2008 - Evidence in context: One person's poison is another's acceptable risk (Editorial)
- ACC plans tighter controls on cox-2s. Meylan, Greg // New Zealand Doctor;11/3/2004, p3
Reports on the plan of ACC to put cox-2 inhibitors on special authority due to concerns about their effectives and side effects. Reason of ACC for funding cox-2; Role of Pharmac in placing cox-2 inhibitors on a special authority; Advice of ACC for physicians who had prescribed Vioxx to their...
- Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. Behan, K.; Cutts, C.; Tett, Susan E. // European Journal of Clinical Pharmacology;Mar2005, Vol. 61 Issue 1, p55
This study compared the changes over time in the volume of prescriptions of COX-2 selective inhibitors between rural and urban Queensland to reveal any difference in the uptake of the prescribing of these new drugs between two geographically distinct areas. This study used data from an...
- Effect of Vioxx withdrawal on COX-2 inhibitor prescribing. // PharmacoEconomics & Outcomes News;11/6/2004, Issue 465, p3
Reports on the effect of Vioxx withdrawal on the prescription of COX-2 inhibitors. Reaction of physicians to the withdrawal; Factors that may influence the prescribing of COX-2; Comments from NOP World Health director Andrea McDonough on the issue.
- Etoricoxib superior to prior NSAID treatment in Mexico. // PharmacoEconomics & Outcomes News;6/19/2005, Issue 455, p10
Presents a study which evaluated the effectiveness of cyclooxygenase-2 inhibitor etoricoxib in improving quality of living, pain and physical function of patients in Mexico. Satisfaction of physicians and patients on the effect of the drug.
- Medsafe reviewing cox-2 advice for GPs. Kumar, Rajesh // New Zealand Doctor;10/20/2004, p4
Reports on the review of the safety of cox-2 inhibitors by Medsafe in New Zealand after the product recall of rofecoxib, an inhibitor from Merck Sharp and Dohme. Uncertainty of physicians over the safety of prescribing other inhibitors to their patients; Differences among other manufactured...
- Non-steroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia. Barozzi, Nadia; Tett, Susan E. // BMC Health Services Research;2008, Vol. 8, Special section p1
Background: Cross national drug utilization studies can provide information about different influences on physician prescribing. This is important for medicines with issues around safety and quality of use, like non selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) and...
- 'Safe' arthritis pain relievers. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p33
Reports on the identification of cox-2 inhibitors as the relatively safe and effective nonprescription alternatives in relieving arthritis pain. Link of arthritis pain relief to heart disease; Sales of cox-2 inhibitors.
- Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data. Edwards, Jayne E.; Moore, R. Andrew; McQuay, Henry J. // BMC Women's Health;2004, Vol. 4, p5
Background: Individual patient meta-analysis to determine the analgesic efficacy and adverse effects of single-dose rofecoxib in primary dysmenorrhoea. Methods: Individual patient information was available from three randomised, double blind, placebo and active controlled trials of rofecoxib....
- Efficacy and safety of COX 2 inhibitors. Jones, Roger // BMJ: British Medical Journal (International Edition);9/21/2002, Vol. 325 Issue 7365, p607
Editorial. Discusses the efficacy and safety of cyclo-oxygenase 2 (COX 2) inhibitors. Upper gastrointestinal damage induced by non-steroidal anti-flammatory drug use; Introduction of new anti-inflammatory agents; Possible side effects.